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ALTERNATIVE OPIOID SPARING TREATMENT OPTIONS FOR  
ACUTE PAIN MANAGEMENT THERAPY 
HANNA CACACE 
ABSTRACT 
The vast array of causes, mechanisms, and interventional strategies for pain has 
created an extensive field of research spanning a variety of disciplines. This thesis aims 
to describe the multidimensional factors leading to pain, how pain can be assessed, and 
how we can best target these pain pathways to improve acute pain management. 
Although opioids have been used for centuries in many analgesic therapies, new research 
and public concern are increasingly deterring clinicians from prescribing them. This 
thesis will discuss opioid’s mechanism of action, risk of adverse effects, and limitations. 
Furthermore, the ‘opioid crisis’ will be examined from its beginning to where we are 
now. Alternative pharmacological and nonpharmacological therapeutic options are 
presented in the hope of exposing opioid-sparing improvements to analgesia; their 
mechanism of action, efficacy, and limitations are described where applicable.   
Beyond individual analysis and evaluations of reputable, highly cited studies for 
each therapeutic option, this thesis also examines multimodal analgesia and how it is 
changing acute pain management. Multimodal analgesia allows multiple dimensions of 
the pain pathway to be targeted by using multiple drugs, leading to greater pain relief, 
decreased doses of medications, and reduced side effects. Multidisciplinary advantages 
are also discussed, including dynamic clinician involvement, individualization, 
organizational procedures, and patient education interventions.  The complexities of pain 
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management therapy and suggestions for future directions presented in this thesis are 
intended to expose additional options or techniques to ultimately improve surgical 
outcomes, increase patient satisfaction, and decrease public health risks.  
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INTRODUCTION 
I. Pathophysiology of pain  
Adequate analgesia requires a general understanding of the pathophysiology of 
pain, how to assess the patient’s pain, and awareness of the variety of therapeutic options 
available. The International Association for the Study of Pain defines pain as the 
“unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage” (Loeser et al., 2011). Pain is more than an 
uncomfortable sensation, when analgesia is not effective there is a much greater risk for 
adverse effects such as respiratory/cardiovascular complications or infections, slowed 
discharge and rehabilitation, persistent or chronic postoperative pain, inadequate long-
term functioning and increased costs to the patient or health system (Chou et al., 2016; 
Lovich-Sapola et al., 2015). Chronic postsurgical pain refers to intractable acute pain, 
typically due to inadequate postoperative pain management therapy, and is one of the 
care team’s greatest concern because of the substantial impact it can have on the patient’s 
affective mood, sleep, and quality of life (Khan et al., 2011). To fully understand pain 
and analgesia, the contributions and interplay of physiological, psychological, and 
environmental factors should all be considered.  
 
Physiological 
Acute pain is classified as nociceptive or neuropathic, resulting from trauma-
induced inflammation or direct nerve injury respectively (Lovich-Sapola et al., 2015). 
Whether neuropathic or nociceptive, the ‘pain sensation’ involves the interplay of 
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peripheral and central mechanisms and corresponding pathways. Peripheral mechanisms 
begin when a peripheral nerve, specifically the primary afferent nociceptor, detects a 
painful stimulus. Primary afferent nociceptors (pain receptors) will transmit this signal to 
the dorsal horn as well as release polypeptide mediators from their termini. The release of 
mediators such as substance P can induce vasodilation, mast cell degranulation, leukocyte 
chemoattraction, and increased mediator release for inflammation. This ‘neuroeffector’ 
function of primary afferent nociceptors uniquely classifies these nerve fibers as more 
than messengers of signals and active participators in tissue protection (Rathmell & 
Fields, 2018). Figure 1 illustrates the direct activation and secondary activation of 
primary afferent nociceptor terminals and subsequent sensitization and its spread. 
 
 
Figure 1. Activation of primary afferent nociceptor terminals and subsequent 
events. (A) Direct activation of the pain receptor following cell damage and transmission 
to the spinal cord. Damaged cells induce prostaglandin (PG) and bradykinin (BK) 
synthesis and local increase in hydrogen (H+) and potassium (K+) ions, all of which 
stimulate the nociceptor termini. (B) Impulses travel to other terminal branches in 
addition to the spinal cord and cause “secondary activation,” which induces mediator 
peptide release such as Substance P (SP) which can stimulate histamine (H) and serotonin 
(5HT) release as well. (Figure taken from Kasper et al., Harrison’s Principles of Internal 
Medicine, 2015).  
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The impulses travel down the primary afferent nociceptor to the dorsal root, 
where the central mechanisms of pain begin. The primary afferent nociceptor terminal 
will release neurotransmitters and peptides to excite multiple spinal cord second-order 
neurons. Neurotransmitters and peptides include glutamate, substance P, and calcitonin 
gene-related peptide. It should be noted that spinal neurons also receive convergent 
inputs from many primary afferents. Bulbospinal pathways are able to regulate pain 
transmission here via neurotransmitters such as serotonin and norepinephrine (Rathmell 
& Fields, 2018).  
Second-order spinal neurons cross in ascending pathways to the thalamus, known 
as the spinothalamic tract. Thalamic projections then go to the somatosensory cortex or 
frontal cortex, each illustrating different components of the pain stimulus. There is also a 
pain-modulation network which controls pain-transmission cells in the spinal cord via 
frontal cortex and hypothalamus inputs, as illustrated in Figure 2. The psychological 
variability in perceived pain can be explained by these brain circuits which modulate pain 
pathway activity (Rathmell & Fields, 2018).  
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Figure 2. Transmission and modulation of pain pathways. A. Noxious stimuli will 
activate primary afferent nociceptors via transduction. Peripheral nerves transmit the 
message to the spinal cord, which synapse with cells in the ascending spinothalamic tract. 
The thalamus will project to the somatosensory cortex (SS), frontal insular (F), and 
anterior cingulate (G). B. The midbrain receives inputs from the hypothalamus and 
frontal cortex and control spinal pain-transmission cells via the medulla. This illustrates 
the pain-modulation network. (Figure taken from Kasper, et al., Harrison’s Manual of 
Medicine, 2015).   
 
When tissue destruction occurs, the release of local inflammatory mediators can 
produce hyperalgesia and/or allodynia. Hyperalgesia is the increased sensitivity to stimuli 
in the area surrounding an injury due to peripheral pain receptor sensitization or increased 
excitability of central neurons and allodynia is the misperception of pain to nonnoxious 
stimuli (Kodali & Oberoi, 2014).  
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Genetics are another important consideration for understanding pain and 
analgesia. The pharmacokinetics and pharmacodynamics of analgesic drugs varies 
between patients because genetic differences in transporters, metabolizing enzymes, 
signal transduction elements, or receptors can all effect the plasma concentrations of the 
active metabolite as well (Lovich-Sapola et al., 2015). For example, recent studies have 
shown single nucleotide polymorphisms in the genes for catechol-O-methyltransferase or 
the mu-opioid receptor are correlated with basal pain sensitivity differences, response to 
opioids, altered mu-opioid receptor binding, and even the progression from acute to 
chronic pain (Diatchenko et al., 2005; Fillingim et al., 2005). 
 
Psychological 
 Pain-transmission pathways can be modulated by brain circuits as well, where 
spinal pain-transmission neurons can be controlled via a descending pathway from the 
medulla, midbrain, and hypothalamus. This can alter the perceived intensity of pain and 
can explain the power of expectation, suggestion, placebo, and nocebo effects. To 
illustrate this, consider a professional athlete who sustains a serious fracture and feels 
minimal pain or the analgesic effect felt after just a suggestion that a certain (placebo) 
treatment will relieve pain (Rathmell & Fields, 2018).  
 
Environmental 
Twin studies using animals and humans have evaluated the effect of 
environmental factors on pain sensitivity. Interestingly, the environmental contributions 
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to variability in pain sensitivity and the pressure-pain threshold were equal for animals 
and humans and showed a considerable effect of approximately 10% difference in values 
(Nielsen et al., 2009). Such environmental factors include social support, perceived 
reception of others, surgical unit and care team, and level of external stress felt by the 
individual (Nielsen et al., 2009; Sng et al., 2009). 
 
Pain Assessments 
In addition to how an individual’s psychological state can impact the actual pain 
sensation, the psychological assessment of the pain by the patient and clinician is 
important to consider. Pain assessments are necessary to evaluate whether adequate pain 
management has been achieved (Chou et al., 2016). Patient-reported subjective values are 
the primary basis for all validated pain scales and objective clinician opinions are 
inaccurate, unreliable, and should never be used.  One of the most widely accepted scales 
is the Visual Analogue Scale (VAS), which utilizes a 100-millimeter horizontal line with 
“no pain” and “worst pain” at opposite ends. The VAS scale has established validity 
because of its strong correlations to numeric pain intensity scales and sensitivity to 
changes in pain perception (Coll et al., 2004). This lends itself to being one of the most 
commonly used scales for analgesic studies. 
 
Pain Relief 
Opium was discovered in the 1500s and quickly became known for its pain-
relieving capabilities (Hebbes, 2016; Yaksh & Wallace, 2018).  Research into opium’s 
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effects eventually led to the discovery of four distinct opioid receptors and classes of 
endogenous opioid ligands (Yaksh & Wallace, 2018). Endogenous opioid 
ligands/peptides are present in our brain and function in reward pathways, modulate 
responses to stressors and painful stimuli, and have roles in homeostatic pathways (Koob, 
1992). Pharmacological opioids include morphine, fentanyl, oxycodone, and tramadol.  
Further research into opioid receptors and ligand binding sites demonstrated their 
expansive distribution not only in the central nervous system, on cell somas and termini 
in the brain and spinal cord, but also in the periphery, in places such as the 
gastrointestinal tract and macrophage cell membrane. The wide distribution helps 
illustrate the variety of adverse effects associated with opioids, the most common listed 
are in Table 1 (Yaksh & Wallace, 2018).  
 
 
Table 1. Opioid-related adverse effects. (Table adapted from Lovich-Sapola et al., 
2015). 
 
 
Adverse Effect Comment 
Respiratory Depression Dose related 
Nausea/vomiting Dose related, can reduce with antiemetics 
Impaired gastrointestinal 
motility 
Can reduce using peripheral-acting opioid antagonists 
Urinary retention  
Severe itching  
Delirium/cognitive 
dysfunction 
 
Tolerance and hyperalgesia Tolerance: anti-nociceptive pathways become 
desensitized to opioids.  
Hyperalgesia: pro-nociceptive pathways become 
hypersensitized to pain. 
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The analgesia provided by opioids is through modulation of central mechanisms 
in the pain pathway, activating inhibitory neurons and directly inhibiting the pain-
transmission neurons. Most opioids on the market will act at the same receptor (mu) but 
differ in pharmacological properties such as route of administration, potency, and/or 
duration of action (Rathmell & Fields, 2018). For example, morphine and fentanyl given 
using the same route of administration have time to onset of 6 minutes and 2 minutes, 
respectively, and their duration of effect range from approximately 84 minutes to 2 
minutes (Helander et al., 2017). 
 
The “Opioid Epidemic”  
Opioids are concerning because of their risk of adverse effects, addiction, 
tolerance, wide range of interpatient variability, and proven inferiority for pain relief in 
comparison to newer protocols (Yaksh & Wallace, 2018). Although effective 
pharmacologically as analgesic agents, their tendency for misuse and abuse has led to a 
“prescription painkiller overdose epidemic,” as termed by the Centers for Disease Control 
(CDC). Both the number of deaths due to prescription opioids and amount of opioid 
prescriptions have quadrupled in the last 18 years (“Understanding the Epidemic,” 2017). 
Soon after the CDC ‘epidemic’ classification, the Agency Medical Directors Group 
(AMDG) Interagency Dosing Guidelines were created. Although acknowledging the 
benefit of opioids for certain acute pain management therapy when prescribed and 
managed properly, the Guidelines’ main objective is to reduce overall opioid prescribing. 
The high risk for acute cases turning into “chronic disabilities due to unnecessary, 
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ineffective, and potentially harmful chronic opioid analgesic therapy” was the driving 
force behind this objective (Javaher & Mai, 2015). 
Unlike chronic pain, acute pain is due to distinct tissue trauma that brings the 
patient to the hospital for surgery, or to the emergency room, and should heal within three 
months (Hilliard, 2015). Approximately 98.6% of surgical patients will receive opioids at 
some point during their hospitalization and more than 10% of these patients show 
progression to chronic opioid use, defined as a time period greater than three months 
(Kaplovitch et al., 2015). Once patients have used opioids for at least three months, they 
are now more than 60% likely to still be on opioid therapy for five or more years; this 
refers to the guideline’s intention of reducing iatrogenic, chronic disabilities (Javaher & 
Mai, 2015). Furthermore, once access to a prescription is lost (for example, when a 
provider deems the end of an acute analgesia period), there is an increasingly common 
transition to heroin, as it can serve as a sufficient, inexpensive, and easily accessible 
replacement in those now feeling withdrawal and addictive symptoms (Kolodny et al., 
2015). Even if the patient does not transition to heroin and remains prescribed opioid 
therapy, opioids for chronic pain lack any convincing evidence that they are able to 
improve functional outcomes and instead have a clear association with harm and adverse 
events, including death (Reuben et al. 2015, Javaher & Mai, 2015). If a patient begins 
long-term opioid therapy, tolerance or dependence always develops to some degree, one 
out of four will become a non-medical user, and one out of 10 will show addictive 
behaviors and features (Vowles et al., 2015). Stated in the AMDG guidelines, by 
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“preventing a transition from acute and subacute pain to chronic pain and disability… 
(we can) have a significant impact on saving productive lives (Javaher & Mai, 2015).”  
One theory for the sudden increase in opioid use points to campaigns by The 
American Pain Society in the 1990s that we need to increase pain treatment and 
simultaneously published weak evidence that opioids could possibly be a good treatment 
for chronic pain management, later followed by Purdue Pharma marketing of OxyContin 
in 1996 convincing physicians that opioids could be used chronically without tolerance, 
dependence, or high risk of overdose (Max et al., 1995; Portenoy & Foley, 1986; Van 
Zee, 2009). The opioid prescription rate began its dramatic rise, eventually reaching a 
700% increase (Strayer et al., 2017). Not only did this directly increase opioid 
prevalence, but efficacy is so low in chronic pain management that high dosages must be 
used, previous opioid exposure complicates acute-use when these patients present in the 
operating room, and potential for abuse is increased (Hilliard, 2015). In fact, Purdue 
Pharma received a $634 million felony conviction for “misleading doctors, patients, and 
regulators about OxyContin’s abuse liability” (Strayer et al., 2017). 
 Optimizing pain management therapy will continue to gain significance, 
especially given the morbidity and mortality rates associated with the current opioid 
epidemic state. A surgical patient may be introduced to opioids for the first time, and 
indiscriminate opioid prescriptions add overdose, addiction, and adverse event threats to 
their operation and its own associated risks (Kumar et al., 2017). On the other hand, there 
is also an increasing proportion of surgical patients who present as opioid-tolerant, 
having been exposed previously whether prescribed for a chronic condition or by 
 11 
obtaining illegally. These patients have added risks of inadequate pain relief (due to 
tolerance), relapse, or overdose and analgesic therapy must be carefully individualized 
(Kumar et al., 2017).  
For any patient, the goal of analgesic therapy should be to prescribe the most 
limited and/or low-dose of opioids in a multimodal regimen, which includes multiple 
drugs with different targets and mechanisms of action (Javaher & Mai, 2015). 
Multidisciplinary approaches are also gaining traction for their potential to reduce opioid 
prescriptions and improve recovery. Accelerated recovery protocols now incorporate 
optimized preoperative ‘prehabilitation’ (rehabilitation starting before the surgical 
procedure) and preparation, perioperative surgical stress attenuation, postoperative pain 
control, and rehabilitation processes. 	
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SPECIFIC AIMS 
 
Specific aims of this thesis include: 
1. Investigation of the current opioid epidemic and its implications. 
2. Comprehensive review of literature analyzing alternative, opioid-sparing 
interventions including efficacy, practicality, and benefits for acute analgesia. 
3. Discuss contradictions and short-comings in the literature and possible flaws in 
the published results and studies. 
4. Propose future directions for opioid-sparing acute pain management therapy and 
how they may be implemented. 
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LITERATURE REVIEW 
In December 2015, The American Pain Society (APS), the American Society of 
Anesthesiologists, and the American Society of Regional Anesthesia and Pain Medicine 
commissioned the production of clinical practice guidelines for evidence-based 
postoperative pain management, the “Guidelines on the Management of Postoperative 
Pain” (Chou et al., 2016). The report includes preoperative education, perioperative 
planning, pharmacological and nonpharmacological options for use, policies for 
organizations, and techniques for transitioning to outpatient care. 
A simplified pathway of pain transmission is presented in Figure 3 with numbers 
corresponding to the potential targets for therapeutic analgesia (Hebbes, 2016). 
Modulation of peripheral mechanisms include (1) reducing activation of nociceptors or 
(2) increasing the threshold for signal transmission. Modulation of central mechanisms 
include (3) disrupting afferent transmission in the spinal cord and (4) modulating central 
transmission. 
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Figure 3. Nociceptive pathways and locations for intervention. Peripheral and central 
divisions of the nociception pathway, with corresponding pharmacological interventions. 
Most of which are described in extensive detail in the following sections, including 
specific mechanisms of action. (Figure taken from Hebbes, 2016). 
 
In the peripheral nervous system, pain perception can be modified by reducing 
tissue inflammation and noxious stimuli, therefore reducing the hormonal response to 
injury. Pharmacological examples of this include NSAIDS and COX-2 inhibitors (Kasper 
et al., 2015). Local anesthetics also work here by directly blocking pain receptor activity. 
Drugs acting in the central nervous system such as opioids, ketamine and gabapentinoids 
(including gabapentin and pregabalin) typically act by targeting specific 
neurotransmitters or neurotransmitter receptors (Lovich-Sapola et al., 2015). 
Recommendation 6 from the APS Guidelines recommends multimodal analgesia 
for maximal pain relief, using multiple medications and techniques as well as 
nonpharmacological interventions (Chou et al., 2016). The ideal protocol will vary 
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between each surgery, patient, and setting, however, I will present the most widely 
accepted and effective adjuvants to consider in multimodal analgesia therapy. A summary 
of the analgesic techniques explored in this thesis are summarized in Table 2 (modified 
from Yaksh & Wallace, 2018). 
Table 2. Common pharmacological analgesic options for acute pain management 
therapy. APS recommendation numbers are included in parenthesis if applicable. 
(modified from Yaksh & Wallace, 2018; Chou et al., 2016).  
 
Administrati
on 
Drug Class Examples Action Site of 
Action 
APS 
Recommendation 
Systemic NSAIDs Ibuprofen, aspirin,  Nonspecific 
COX 
inhibitors 
Peripheral 
and 
Central 
Yes (#15) 
COX-2 Inhibitor Celecoxib, 
acetaminophen 
COX-2 
selective 
inhibitor 
Peripheral 
and 
Central 
Yes (#16) 
Opioids Morphine  Mu receptor 
agonist 
Central  
Gabapentinoids Gabapentin, 
pregabalin 
Less Na+ and 
Ca2+ channel 
action 
Central Yes (#17) 
NMDA receptor 
antagonist 
Ketamine NMDA 
receptor 
antagonism 
Central Yes (#18) 
Alpha2 agonists Clonidine, 
dexmedetomidine 
Suppress 
ascending 
noradrenergic  
Central  
Tricyclic 
antidepressants 
Amitryptiline Inhibit 
serotonin and 
norepinephrine 
uptake 
Central  
Local and/or 
Topical 
Site-specific 
local anesthetic 
infiltration 
Bupivacaine  Subcutaneous 
and/or 
intraarticular 
infiltration of 
long acting 
anesthetics 
Peripheral Yes (#20) 
Regional Site-specific 
peripheral 
regional 
anesthesia 
Local anesthetics 
(ex. Lidocaine) via 
single injection, 
continuous, and/or 
ultrasound guided 
Peripheral 
nerve blocks, 
suppress 
afferent pain 
transmission 
Peripheral Yes (#23 and #24) 
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injection 
Neuraxial Epidural/ spinal 
analgesia  
Local anesthetics 
via epidural or 
spinal 
administration 
Suppress 
afferent pain 
transmission, 
inhibit 
sensitization 
Central Yes (#26) 
 
Multimodal therapy 
Multimodal analgesia involves the use of a variety of pharmacological and 
nonpharmacological techniques that target different mechanisms of action, typically 
lessening the local hormonal response to injury and reducing activity of the pain receptor 
(Chou et al., 2016, Lovich-Sapola et al., 2015). This could include multiple medications 
acting at different receptors in the central and/or peripheral nervous system or different 
administration of medications, such as systemic and neuraxial (Chou et al., 2016). When 
approached in this way, the various combinations have proven to have additive and 
synergistic effects leading to greater pain relief (Chou et al., 2016). 
The American Society of Anesthesiologists promotes multimodal acute pain 
management whenever possible (Helander et al., 2017). Pharmacologically, this means 
utilizing a variety of drugs with various mechanisms of action and targets in the pain 
pathways. By approaching pain in a multimodal and more balanced way, the therapeutics 
act in additive and/or synergistic capacities for analgesia and reduce side effects 
(Helander et al., 2017). Patient outcome improvements including decreased pain and 
reduced opioid-related side effects are most commonly achieved when analgesia 
incorporates centrally and peripherally acting analgesic drugs. Although opioids may still 
be used in some of these protocols, much less are needed and therefore the adverse 
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effects, risk of addiction or tolerance, and prescription prevalence are also significantly 
decreased (Elvir-Lazo & White, 2010). 
For any patient, the goal of analgesic therapy should be to prescribe the most 
limited and/or low-dose of opioids in a multimodal regimen (Javaher & Mai, 2015). 
Pharmacologically, this means utilizing a variety of drugs with various mechanisms of 
action and targets in the pain pathways. By approaching pain in a multimodal and more 
balanced way, the therapeutics act in additive and/or synergistic capacities for analgesia 
and reduce side effects (Helander et al., 2017). Multidisciplinary approaches are also 
gaining traction for their potential to reduce opioid prescriptions and improve recovery. 
Accelerated recovery protocols now incorporate optimized preoperative ‘prehabilitation’ 
and preparation, perioperative surgical stress attenuation, postoperative pain control, and 
rehabilitation processes. Although opioids may still be used in some of these protocols, 
much less are needed and therefore the adverse effects, risk of dependence, and 
prescription prevalence are also significantly decreased (Elvir-Lazo & White, 2010).	
Pharmacological multimodal therapy should avoid combinations of drugs with the 
same kinetics or combinations that have overlapping targets and opposing effects (Yaksh 
& Wallace, 2018). Multimodal acute pain management can include nonpharmacological 
approaches as well. Nonpharmacological approaches include physical approaches such as 
acupuncture and transcutaneous electrical nerve stimulation or cognitive-behavioral 
therapy including relaxation techniques or music therapy. Multimodal analgesia may 
serve to improve recovery, decrease surgical complications that can lead to delayed 
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hospital discharge, and reduce recovery time, allowing patient’s to return to normal day-
to-day life earlier (Elvir-Lazo & White, 2010). 
 
Pharmacological Recommendations 
Cyclooxygenase inhibitors  
 Cyclooxygenase inhibitors include acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs, which include ibuprofen, ketorolac, and aspirin), and 
COX-2 selective inhibitors (including celecoxib). NSAIDs and COX-2 selective 
inhibitors have anti-inflammatory and antipyretic effects by reducing inflammatory 
mediators at the site of tissue damage (Lovich-Sapola et al., 2015). Arachidonic acid is 
released when a tissue is damaged and is metabolized to prostaglandins by 
cyclooxygenases (COX-1 and COX-2). Prostaglandins react with peripheral nociceptors 
and lower the pain threshold. NSAIDS inhibit the cyclooxygenases and therefore 
prostaglandin synthesis, accounting for their pain relieving effects (Helander et al., 2017). 
Most NSAIDs are non-selective i.e. they inhibit both COX-1 and COX-2 isoenzymes. 
COX-1 is constitutively active in various systems in our body whereas COX-2 is only 
induced following tissue injury. Because of this, it makes sense that drugs selective for 
COX-2, such as acetaminophen and celecoxib, have an improved side effect profile 
(Frampton & Quinlan, 2009). Therefore, limitations to NSAID use involving associated 
risks to the renal, gastrointestinal, and cardiovascular systems (where COX-1 is active) 
are reduced when using selective COX-2 inhibitors (Chou et al., 2016). Acetaminophen 
is considered separately because its main mechanism of action is through increasing 
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painful stimuli threshold and lacks significant anti-inflammatory activity, as it only 
weakly inhibits the cyclooxygenase enzyme (Yaksh & Wallace, 2018). 
NSAIDs are recommended by the APS as an around-the-clock systemic 
therapeutic, with Celecoxib beginning in the preoperative stage. Celecoxib given 
preoperatively has proven to reduce postoperative pain and opioid consumption where as 
non-selective NSAIDS do not have sufficient evidence, per the panel, for a significant 
benefit (Chou et al., 2016). Postoperative dosing of celecoxib has also provided 
significantly improved patient variables as well. A placebo-controlled study by White et 
al. found that three days of postoperative celecoxib dosing reduced patients’ pain and 
opioid consumption. They also found that the celecoxib group was able to resume normal 
daily activities one to two days sooner (White et al., 2007) 
A study published in JAMA last year (2017) compared the efficacy of three 
opioid-acetaminophen combinations and an ibuprofen-acetaminophen combination for 
acute pain in the emergency department (Chang et al., 2017). The results showed no 
significant difference in pain reduction across the four combinations within two hours 
post-dosing. Chang et al. go on to argue that distinctions between oral analgesics are 
incorrect, including the World Health Organization recommendations for a prescribing 
‘ladder’ where non-opioids are prescribed first and then opioids if necessary, based on 
pain-intensity (Chang et al., 2017; Yaksh & Wallace, 2018).  
This study’s results counteract this school of thought and defend the notion that 
opioids may be wrongly classified as more powerful analgesics (Chang et al., 2017). 
Furthermore, when opioid-only therapy is compared to opioid plus acetaminophen and/or 
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NSAIDs, multiple studies have concluded that patients receiving the combination have 
significantly less pain than those only using opioids. The addition of NSAIDs and COX-2 
inhibitors can reduce the opioid requirements for the same amount of analgesia by 
approximately 30% (Maund et al., 2011; Wong et al., 2013). 
Many multimodal protocols suggest NSAIDs and acetaminophen are both used. 
Although NSAIDs and acetaminophen seem similar in mechanisms and uses, a 
systematic review involving over 1900 patients concluded that combining NSAIDs and 
acetaminophen is 85% and 64% more effective than acetaminophen or NSAID alone, 
respectively (Ong et al., 2010). Acetaminophen is 30% less effective than NSAIDs in 
pain reduction however it is superior in certain circumstances because it has fewer side 
effects (Mackey et al., 2013). The clinicians biggest concern when dosing acetaminophen 
should involve liver toxicity (Lovich-Sapola et al., 2015). Limitations to NSAID use 
include associated risks to the renal, gastrointestinal, and cardiovascular systems however 
selective COX-2 inhibitors, such as celecoxib, boast reduced risks in at least one of these 
categories (Chou et al., 2016).  
 
Alpha-2 Agonists 
Alpha2 agonists, such as clonidine and dexmedetomidine, have proven to be 
effective analgesics and valuable additions to multimodal therapy (Blaudszun et al., 
2012). Alpha-2 agonists work by stimulating alpha-2 adrenoreceptors on the presynaptic 
neurons within the dorsal horn, inhibiting nociceptive neuronal cascade and calcium ion 
influx, norepinephrine release via negative feedback, and release of Substance P 
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(Giovannitti et al., 2015). This suppression and reduced activity of ascending 
noradrenergic pathways underlies the sympatholytic effects of alpha2 agonists, including 
sedation, anxiolysis, and analgesia (Giovannitti et al., 2015). In addition, decreasing 
norepinephrine levels enhances circulatory stability and decreases cardiovascular 
responses during surgery and immediately postoperatively (Mackey et al., 2013). 
The continuous infusion of dexmedetomidine intraoperatively proved 
advantageous for reducing opioid requirements postoperatively as well as reducing 
opioid-related side effects (Gurbet et al., 2006). In the first 48 hours post-surgery, the 
placebo group had a mean cumulative opioid consumption of 65.8 mg compared to the 
mean cumulative opioid consumption of only 28.6 mg in the group that received 
dexmedetomidine intraoperatively. Perioperative intravenous clonidine has shown similar 
efficacy. A study from 1994 showed administration of intraoperative clonidine was able 
to reduce opioid requirements, pain scores, and occurrence of opioid-related side effects 
postoperatively. Interestingly and also beneficial, the clonidine groups also had less of a 
hemodynamic reaction when making the surgical incision (De Kock et al., 1994). 
A meta-analysis of 10 clonidine trials showed significant reduction of post-
operative opioid equivalent consumption at the 12 and 24-hour marks postoperatively, 
32% and 25% reduction respectively (Blaudszun et al., 2012). Dexmedetomidine is a 
newer alpha2 agonist with a more preferable adverse-effect profile and eight times more 
specific for alpha2 receptors vs. alpha1 receptors compared to clonidine (Mackey et al., 
2013). A meta-analysis including eight trials on dexmedetomidine were analyzed and 
found significant reduction of opioids starting at two hours postoperatively and ranging 
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from 40% to 25% over the 24 hours following surgery (Blaudszun et al., 2012). At the 
24-hour postoperative mark, both clonidine and dexmedetomidine show improved 
analgesia compared to acetaminophen but were not as effective as NSAIDS. Alpha2 
agonists have also shown to have cardioprotective effects following surgery through 
decreasing the risk for arterial hypertension. Blaudszun et al. suggest that 
anesthesiologists may consider using alpha2 agonists to combat hemodynamic stress-
responses during surgery as well as for antiemesis (2012).  
 
Gabapentinoids  
Gabapentinoids exert their effects by inhibiting the trafficking of voltage-gated 
calcium channels to the membrane and decreasing excitatory neurotransmitter release 
(such as glutamate, substance P, norepinephrine, serotonin, and dopamine) causing 
nociceptive blocking (Gajraj, 2007; Hendrich et al., 2008). The APS panel agreed that 
there was sufficient evidence to prove an opioid-sparing effect and reduced pain 
postoperatively when given as a preoperative, perioperative, or postoperative adjuvant 
(Chou et al., 2016; Helander et al., 2017). 
A study by Pandey et al. involving 459 laparoscopic cholecystectomy patients 
compared gabapentin, tramadol, or placebo given preoperatively and recorded the 
patients’ pain scores for the first 24 hours postoperatively (Pandey et al., 2004). The 
patients were also allowed to receive fentanyl on demand as a rescue analgesic and 
consumption was noted. Pain scores at every time interval were significantly lower in the 
gabapentin group compared to tramadol or placebo. Fentanyl consumption was also 
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significantly less in the entire gabapentin group at 221 micrograms, compared to 270 and 
356 in the tramadol and placebo groups respectively (Pandey et al., 2004). 
A similar study by Agarwal evaluated the analgesic effect and fentanyl 
consumption following laparoscopic cholecystectomy when given preoperative 
pregabalin (Agarwal et al., 2008). The pregabalin group had a statistically significant 
reduction of fentanyl consumption and decreased pain scores measured both at rest and 
while moving (Agarwal et al., 2008). An important consideration for gabapentin or 
pregabalin is they are only available as oral formulations currently. Because some 
patients cannot safely ingest oral medication in the immediate postoperative period, the 
APS panel suggests high doses given preoperatively in these situations (Chou et al., 
2016). 
 
NMDA-Receptor Antagonists 
Another mechanism of pain relief is through N-methyl-D-aspartate receptor 
antagonism in dorsal horn neurons (Porter et al., 2015). Ketamine, amantadine, and 
dextromethorphan are examples of drugs that work in this way. When tissue damage 
occurs, glutamate is released from spinal neurons in the dorsal horn. Glutamate will then 
bind to NMDA receptors causing upregulated gene expression for pro-inflammatory 
cytokines (Basbaum et al., 2009). By antagonizing the NMDA receptor, inflammatory 
and nociceptive pain transmission is blocked. Ketamine, however, also provides a degree 
of analgesia through interactions with sodium and calcium channels, dopamine 
cholinergic receptors, and reuptake inhibition of serotonin and norepinephrine (Porter et 
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al., 2015). This is likely to contribute to ketamine’s opioid-sparing effect of up to 40% 
(Kumar et al., 2017). 
Kaur et al. published a study in 2015 analyzing postoperative analgesic effects 
due to intraoperative low-dose infusion of ketamine (Kaur et al., 2015). Only 12.5% of 
the ketamine group required rescue opioid analgesia whereas 100% of the control group 
required it. Statistically this significantly reduced overall morphine consumption from 17 
mg in the control group to 4.6 mg when the subjects had previously been dosed with 
ketamine (Kaur et al., 2015). 
Ketamine is also useful in low doses for acute pain management in the emergency 
department, commonly used for sedation and intubation (Ahern et al., 2013). However, 
recent research documenting its safety, effectiveness, and opioid-sparing analgesia have 
propelled it into new uses for pain management as well in acute trauma cases. A 
retrospective study of 530 emergency department patients receiving low dose ketamine 
did find minor psychomimetic side effects, but in only 3.5% of patients, and overall 6% 
rate of adverse events (Ahern et al., 2015).  
Intravenous ketamine is recommended by the panel as an addition to multimodal 
analgesia however, commonly discussed limitations of ketamine involve concerns over 
its psychotropic side effects, including hallucinations, delirium, and illusions (Chou et al., 
2016; Porter et al., 2015). Although these will negatively impact patient satisfaction, 
using lower doses and/or the addition of benzodiazepines have been shown to decrease 
these side effects (Himmelseher & Durieux, 2005). Furthermore, the APS panel suggests 
ketamine’s use may be particularly designated for patient-specific cases such as opioid-
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tolerance, neuropathic pain, poorly controlled pain, or an inability to tolerate opioids to 
help avoid these side effects to some degree (Chou et al., 2016; Tumber, 2014). 
Snijdelaar et al. showed the efficacy of perioperative amantadine for patients 
undergoing a prostatectomy (Snijdelaar et al., 2004). Compared to the placebo group, the 
group given amantadine consumed 32% less opioids during the first 48 hours post 
operation and reported less operative pain. The researchers also measured the patient’s 
pain after applying external pressure near the surgical wound 48 hours after the operation. 
The amantadine group had a statistically significant reduction in reported pain (Snijdelaar 
et al., 2004). 
 
Glucocorticoids 
Glucocorticoids are used in a variety of conditions to decrease inflammation and 
tissue damage, modulate immune responses (relevant to allograft rejection), and reduce 
emesis (Barnes, 2005). Their analgesic effect on postoperative pain is attributed to 
inhibiting pro-inflammatory mediators and enzymes (such as COX-2) and suppressing 
transcription factors involved in inflammatory gene expression (Barnes, 2005).  
Perioperative dosing of dexamethasone, a glucocorticoid, has recently shown analgesic 
effects for postoperative pain and need for opioids as well (Waldron, et al., 2013). A 
study by Kjetil et al. showed that dexamethasone’s prolonged analgesic effects are three 
times greater when added to a combination of acetaminophen, an NSAID, and a local 
infiltration anesthetic (Kjetil et al., 2007). Methylprednisolone is another glucocorticoid 
proven effective for postoperative pain in certain surgeries. A study by Romundstad et al. 
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tested the efficacy of methylprednisolone given prior to breast augmentation surgery. 
They propose the pressure-related and inflammatory nature of the immediate 
postoperative pain provides a valid clinical model for how anti-inflammatory drugs may 
provide pain relief. In this study, methylprednisolone reduced pain intensity and the 
amount of rescue opioid requested compared to placebo (Romundstad et al., 2006). 
Additional studies by the same Principal Investigator however still proved analgesic 
effects in primarily non-inflammatory or pressure-related postoperative pain models as 
well, for example orthopedic surgeries (Romundstad et al., 2004). 
 Corticosteroid use in surgical patients has been historically avoided due to 
associated potential risks including impaired wound healing, infection, and 
hyperglycemia. However, recent studies evaluating these concerns show that short term 
administration does not cause any of these adverse events (Helander et al., 2017; Snäll et 
al., 2013).  
 
Tricyclic Antidepressants/SNRIs 
 Antidepressants such as amitriptyline and duloxetine can produce analgesic 
effects via blocking serotonin-norepinephrine reuptake as well as by blockage of voltage-
gated sodium channels, spinal NMDA receptor antagonism, and a modulating effect on 
descending inhibitory pain pathways (Mackey et al., 2013; Wang et al., 2016; Kumar et 
al., 2017). One limitation to their use as analgesic agents is the delay until complete 
effect, typically lasting one or more weeks. Tricyclic antidepressants are most effective 
for neuropathic pain resulting from nerve damage secondary to stroke, spinal cord injury, 
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peripheral neuropathy, etc. (Mackey et al., 2013). Because this paper is focused on acute 
pain management following surgical intervention and database searches have not found 
significant evidence for clear efficacy, this will not be discussed further.   
 
Local and/or topical pharmacological therapies 
Surgical site-specific local anesthetic infiltration can help reduce postoperative 
pain in specific surgeries, such as Cesarean section, total knee replacements, or 
laparotomies (Chou et al., 2016). Administration of local anesthetics into the surgical 
field provides pain relief via direct inhibition of the inflammatory response and afferent 
pain transmission signaling. This includes wound infiltration and subcutaneous and/or 
intraarticular injection of long-acting local anesthetics in various forms including 
liposomal bupivacaine (Argoff, 2014). A systematic review of intra-articular local 
anesthetics by Møiniche et al. found statistically significant pain relief, however only for 
a short period of time following the surgical procedure (Møiniche et al., 1999). Wound 
infiltration has shown clinical benefits in some studies as well although much more 
variable (Møiniche et al., 1998). It should be noted that the efficacy of most local and 
topical techniques greatly fluctuates because of the specificity of administration and 
minimal area of action therefore, general analgesic and opioid-sparing data is irrelevant. 
 
Neuraxial Analgesia  
Anesthesia and analgesia have long been used to reduce pain during operations 
however newer techniques are proving to decrease reported pain in the postoperative 
 28 
period as well. Neuraxial analgesia involves the local administration of an anesthetic 
and/or opioid around the nerves of the central nervous system to reduce afferent pain 
transmission and inhibit central sensitization from developing (Argoff, 2014). This 
includes epidural and spinal analgesia and regional, peripheral, and local nerve blocks. 
Regional nerve blocks target the surgical field. Peripheral nerve blocks target the nerve 
innervating the surgical field. Local nerve blocks target local tissues in the surgical field.  
Regional anesthesia is recommended by the APS panel for certain surgical 
procedures such as joint or chest surgeries (Chou et al., 2016). Regional techniques can 
include peripheral nerve blocks using local anesthetics or epidural/spinal analgesia using 
a low dose opioid (Sullivan et al., 2016). Both of these techniques utilize application near 
the nerves that transmit nociceptive signals and are effective at reducing pain and 
systemic opioid requirements (Choi et al., 2013). 
Peripheral nerve blocks, whether single-injection or continuous administration via 
catheter, have shown efficacy for decreasing the postoperative length of stay in the 
hospital and reducing surgery-related complications (Chelly et al., 2001). For upper 
extremity surgery, brachial plexus blocks can be useful for reducing postoperative pain 
scores and opioid consumption whereas lower extremity surgeries typically utilize nerve 
blocks along sciatic of femoral nerve distributions (Oyler et al., 2015). Figure 4 illustrates 
nerve blocks applied to the brachial plexus, where specific dermatomes can be targeted 
depending on what operation is being done (Stein et al., 2010). Furthermore, ultrasound 
guidance allows direct visualization of neural tissue for peripheral administration and is 
recommended if available (Chou et al., 2016; Pyati & Gan, 2007). 
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B. 
 
Peripheral Nerve Block: Interscalene 
Brachial plexus target: Roots (A) 
 
Peripheral Nerve Block: Supraclavicular 
Brachial plexus target: Trunks (B) 
 
Peripheral Nerve Block: Supraclavicular 
Brachial plexus target: Cords (C) 
 
Peripheral Nerve Block: Axillary 
Brachial plexus target: Branches (D) 
 
 
Figure 4. How to utilize the brachial plexus for peripheral nerve blocks. (A.) 
Brachial plexus divided into relevant subdivisions, letters correspond to (B.) where 4 
different nerve blocks can be administered and their corresponding dermatomes 
anesthetized highlighted in dark blue. (Adapted from Stein et al., 2010). 
 
A. 
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Epidural analgesia has been shown to be effective at reducing postoperative pain 
and analgesic consumption following abdominal and thoracic surgeries (Pyati & Gan, 
2007). Epidural analgesia is recommended by the APS panel for major thoracic and 
abdominal surgeries for its ability to reduce postoperative pain scores. However, when 
neuraxial analgesia is used, clinicians must be cautious of more severe adverse events 
such as respiratory depression, hypotension, or compartment syndrome. The panel 
discusses this in the organizational recommendations and suggests any facility that 
performs these have additional policies and procedures in place to ensure safety (Chou et 
al., 2016). 
 
Nonpharmacological Recommendations 
Cognitive-Behavioral 
Cognitive-behavioral modalities are also recommended by the panel as beneficial 
additions to a multimodal approach. Recommendations include relaxation techniques 
such as guided imagery and music, hypnosis, and intraoperative suggestions (Chou et al., 
2016). Such techniques have been shown to alleviate fear and anxiety, and reduce pain 
catastrophizing, defined as “the tendency to magnify the threat value of pain and to feel 
helpless within the context of pain” (Theunissen et al., 2012). Relaxation techniques had 
the most supportive evidence of the cognitive-behavioral suggestions and although they 
are mostly associated with the treatment of chronic pain, a quasi-experiment from 2006 
showed potential benefits for acute pain management in postoperative patients as well. In 
this study, Wong et al. implemented a pre-operative 30-minute educational intervention 
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for the experimental group in addition to the usual care (Wong et al., 2010). The 
intervention included information on strategies for coping with pain and breathing 
relaxation techniques. In the first week following surgery, the experimental group had 
significantly less pain, reduced anxiety, and better self-efficacy (Wong et al., 2010).  
Music therapy also provided evidence of efficacy. A systematic review by Cepeda 
et al. concluded 18.4% less morphine was required in subjects exposed to music for the 
first two hours following surgery compared to no exposure (Cepeda et al., 2013). One 
possible explanation for the efficacy of these therapies is through activation of one’s 
endogenous pain-modulating circuit. Suggestion of pain relief as well as emotional 
distractions away from the pain-causing injury are proven ways to activate this system. 
This is also believed to be how placebo effects work, as endogenous opioids are most 
often still released and provide pain relief (Rathmell & Fields, 2018). 
 
Physical 
Recommendations 7 and 8 include “transcutaneous electrical nerve stimulation 
(TENS), acupuncture, massage, cold therapy, localized heat, warm insufflation, 
continuous passive motion, and immobilization or bracing” (Chou et al., 2016). Although 
none of these therapies will cause harm, sufficient evidence demonstrating effective 
analgesia was only found for TENS by the panel.  
TENS is a non-invasive procedure where electrical currents are sent through 
electrodes placed on the skin. Opioid and alpha2 receptors are activated peripherally and 
opioid, muscarinic, and serotonergic receptors are activated centrally (DeSantana et al., 
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2008). A study from 2005 looked at the efficacy of TENS treatment in acute pain 
management by randomizing real and imitation TENS treatments in 63 patients with 
posttraumatic hip pain (Lang et al., 2007). There was substantial evidence for a 
statistically significant effect, as the real TENS treatment reduced pain by approximately 
33% on a VAS pain scale whereas the imitation TENS treatment only minimally changed 
pain scores (Lang et al., 2007). 
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DISCUSSION 
This thesis introduced 12 opioid-sparing alternative options for acute pain 
management. Although many studies were found for the support and rejection of each 
therapeutic, choices were validated by APS recommendation or presentation in textbooks. 
The efficacy of each varies greatly between operations, as well as differences in patients, 
care teams, and protocols. Because this paper did not focus on a specific surgery, the 
efficacy for each was unable to be presented in a conclusive manner.  
A major discrepancy in the literature for analgesic therapy is that improved 
postoperative analgesia has not demonstrated an improvement in clinically meaningful 
outcomes, such as decreasing morbidity, organ dysfunction, or hospital stay (Liu & Wu, 
2007). One possible reason for this is methodological deficiencies in the experimental 
design, i.e. using “surrogate” study endpoints such as quantitative opioid sparing instead 
of meaningful clinical outcomes such as resumption of daily life (Liu &Wu, 2007). 
Further research should be done to evaluate if postoperative analgesic techniques have an 
effect on mortality and morbidity. 
A general consensus in the literature is the need for individualization, varying 
each postoperative pain management protocol due to the procedure, surgeon, patient 
comorbidities and genetics, synergistic or other interactions in the multimodal therapy, 
etc. The variability and increased workload that this ensues is not negligible however the 
necessity of it is too important to disregard. 
Furthermore, the focus of this thesis on describing each alternative analgesic was 
inherently incorrect. The basis of multimodal analgesia is that the total effect is not 
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simply summative of each therapeutic. Therefore, utilizing a reductionist theory to 
analyze each therapeutic individually really does not correlate with their efficacy in 
multimodal analgesic regimens. More research should be done on the interactions and 
efficacy of various therapeutic combinations to gain a realistic interpretation of analgesia 
and opioid-sparing capabilities. 
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CONCLUSION 
Pain is not easy to describe nor is it easy to treat. The many causes, mechanisms, 
and pathways allow diverse interventional strategies, opioids being only one of them. 
There is no ‘best,’ ‘new,’ or ‘miracle’ drug to present in this thesis. After extensively 
researching alternative, opioid-sparing options, the most effective approach is not only 
multimodal but multidisciplinary as well, including patient-physician communication, 
organizational policies and procedures, and evidence-based multimodal analgesia. It was 
somewhat surprising to discover how necessary each aspect is to providing adequate pain 
relief, maintaining optimal patient satisfaction, and suppressing the current opioid 
epidemic. In conclusion, individualization is the most encompassing answer for how we 
can continue to improve pain management therapy and move away from opioid use, and 
that patient-physician communication is a critical aspect of this. Components of patient-
physician communication involve individualized preoperative education, assessment of 
psychological or medical co-morbidities, and longitudinal active patient engagement and 
dynamic protocols by the care team.  
In addition to achieving greater pain relief, having an active role in the patient’s 
early postoperative period and discharge planning allows the physician to notice 
intervention-related side effects, surgical complications, new issues, or psychological 
barriers that could slow a patient’s recovery. This ultimately leads to enhanced recovery, 
fewer complications, and faster rehabilitation timelines.  
Although opioids have been prominent in pain relief for centuries, increasing 
evidence is proving superior analgesic regimens utilizing multimodal therapeutics and 
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multidisciplinary approaches. Overall, there is no place for a ‘fix-all’ solution, and no 
standardized protocol for acute pain management; individualization and awareness of 
opioid-sparing options will improve pain relief, patient satisfaction, and the long-term 
public health of our country.  
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